Circulating human microRNAs are not linked to JC polyomavirus serology or urinary viral load in healthy subjects

Virology Journal

Lieven J Stuyver²  Luc Tritsmans¹  Tom Van Loy²  Ole Lagatie² 

[1] Janssen Research and Development, Turnhoutseweg 30, 2340 Beerse, Belgium;Janssen Diagnostics, Turnhoutseweg 30, 2340 Beerse, Belgium

关键词: Viral load;    Serology;    Plasma;    Circulating microRNA;    microRNA;    JC polyomavirus;   

Others  :  810727
DOI  :  10.1186/1743-422X-11-41

 received in 2013-12-23, accepted in 2014-02-26,  发布年份 2014

【 摘 要 】

Background

JC polyomavirus (JCPyV) is a widespread human polyomavirus that usually resides latently in its host. It can be reactivated under immunomodulating conditions and cause Progressive Multifocal Leukoencephalopathy (PML). Circulating microRNAs (miRNAs) are emerging as promising biomarkers for several pathologies. In this study, we have investigated whether circulating miRNAs exist that are differentially expressed between JCPyV seropositive and JCPyV seronegative on the one hand or between JCPyV shedders and JCPyV non-shedders on the other hand.

Methods

Human miRNA expression profiling was performed in a small set of plasma samples obtained from seronegative subjects, seropositive shedders and seropositive non-shedders. A set of 10 miRNAs was selected for further analysis in a larger group of samples.

Results

Based on the plasma profiling experiment of 30 samples, 6 miRNAs were selected that were possibly differentially expressed between seropositive and seronegative subjects and 4 miRNAs were selected that were possibly differentially expressed between shedders and non-shedders. Subsequently, expression of these 10 selected miRNAs was assessed in an independent set of 100 plasma samples. Results indicated that none of them were differentially expressed.

Conclusion

This study could not identify circulating human miRNAs that were differentially expressed between plasma from JCPyV seropositive and JCPyV seronegative subjects or between JCPyV shedders and JCPyV non-shedders.

【 授权许可】

   
2014 Lagatie et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

【 参考文献 】

• [1]Ferenczy MW, Marshall LJ, Nelson CD, Atwood WJ, Nath A, Khalili K, Major EO: Molecular biology, epidemiology, and pathogenesis of progressive multifocal leukoencephalopathy, the JC virus-induced demyelinating disease of the human brain. Clin Microbiol Rev 2012, 25(3):471-506.
• [2]Bellizzi A, Nardis C, Anzivino E, Rodio D, Fioriti D, Mischitelli M, Chiarini F, Pietropaolo V: Human polyomavirus JC reactivation and pathogenetic mechanisms of progressive multifocal leukoencephalopathy and cancer in the era of monoclonal antibody therapies. J Neurovirol 2012, 18(1):1-11.
• [3]Markowitz RB, Thompson HC, Mueller JF, Cohen JA, Dynan WS: Incidence of BK virus and JC virus viruria in human immunodeficiency virus-infected and -uninfected subjects. J Infect Dis 1993, 167(1):13-20.
• [4]Tan CS, Dezube BJ, Bhargava P, Autissier P, Wuthrich C, Miller J, Koralnik IJ: Detection of JC virus DNA and proteins in the bone marrow of HIV-positive and HIV-negative patients: implications for viral latency and neurotropic transformation. J Infect Dis 2009, 199(6):881-888.
• [5]Chapagain ML, Nerurkar VR: Human polyomavirus JC (JCV) infection of human B lymphocytes: a possible mechanism for JCV transmigration across the blood-brain barrier. J Infect Dis 2010, 202(2):184-191.
• [6]Knowles WA, Pipkin P, Andrews N, Vyse A, Minor P, Brown DW, Miller E: Population-based study of antibody to the human polyomaviruses BKV and JCV and the simian polyomavirus SV40. J Med Virol 2003, 71(1):115-123.
• [7]Lee P, Plavina T, Castro A, Berman M, Jaiswal D, Rivas S, Schlain B, Subramanyam M: A second-generation ELISA (STRATIFY JCV DxSelect) for detection of JC virus antibodies in human serum and plasma to support progressive multifocal leukoencephalopathy risk stratification. J Clin Virol 2013, 57(2):141-146.
• [8]Major EO: Progressive multifocal leukoencephalopathy in patients on immunomodulatory therapies. Annu Rev Med 2010, 61:35-47.
• [9]Van Loy T, Thys K, Tritsmans L, Stuyver LJ: Quasispecies analysis of JC virus DNA present in urine of healthy subjects. PLoS One 2013, 8(8):e70950.
• [10]Major EO, Frohman E, Douek D: More on JC viremia in natalizumab-treated patients with multiple sclerosis. N Engl J Med 2013, 369(13):1280.
• [11]Major EO, Frohman E, Douek D: JC viremia in natalizumab-treated patients with multiple sclerosis. N Engl J Med 2013, 368(23):2240-2241.
• [12]Stuyver LJ, Verbeke T, Van Loy T, Van Gulck E, Tritsmans L: An antibody response to human polyomavirus 15-mer peptides is highly abundant in healthy human subjects. Virol J 2013, 10:192. BioMed Central Full Text
• [13]Chen Y, Bord E, Tompkins T, Miller J, Tan CS, Kinkel RP, Stein MC, Viscidi RP, Ngo LH, Koralnik IJ: Asymptomatic reactivation of JC virus in patients treated with natalizumab. N Engl J Med 2009, 361(11):1067-1074.
• [14]Viscidi RP, Khanna N, Tan CS, Li X, Jacobson L, Clifford DB, Nath A, Margolick JB, Shah KV, Hirsch HH, Koralnik IJ: JC virus antibody and viremia as predictors of progressive multifocal leukoencephalopathy in human immunodeficiency virus-1-infected individuals. Clin Infect Dis 2011, 53(7):711-715.
• [15]He L, Hannon GJ: MicroRNAs: small RNAs with a big role in gene regulation. Nat Rev Genet 2004, 5(7):522-531.
• [16]Boss IW, Renne R: Viral miRNAs: tools for immune evasion. Curr Opin Microbiol 2010, 13(4):540-545.
• [17]Kincaid RP, Sullivan CS: Virus-encoded microRNAs: an overview and a look to the future. PLoS Pathog 2012, 8(12):e1003018.
• [18]Leidinger P, Backes C, Deutscher S, Schmitt K, Mueller SC, Frese K, Haas J, Ruprecht K, Paul F, Stahler C, Lang CJ, Meder B, Bartfai T, Meese E, Keller A: A blood based 12-miRNA signature of Alzheimer disease patients. Genome Biol 2013, 14(7):R78. BioMed Central Full Text
• [19]Guay C, Regazzi R: Circulating microRNAs as novel biomarkers for diabetes mellitus. Nat Rev Endocrinol 2013, 9(9):513-521.
• [20]Madhavan D, Cuk K, Burwinkel B, Yang R: Cancer diagnosis and prognosis decoded by blood-based circulating microRNA signatures. Front Genet 2013, 4:116.
• [21]Kawano Y, Iwata S, Kawada J, Gotoh K, Suzuki M, Torii Y, Kojima S, Kimura H, Ito Y: Plasma viral microRNA profiles reveal potential biomarkers for chronic active Epstein-Barr virus infection. J Infect Dis 2013, 208(5):771-779.
• [22]Tambyah PA, Sepramaniam S, Mohamed Ali J, Chai SC, Swaminathan P, Armugam A, Jeyaseelan K: microRNAs in circulation are altered in response to influenza A virus infection in humans. PLoS One 2013, 8(10):e76811.
• [23]Winther TN, Bang-Berthelsen CH, Heiberg IL, Pociot F, Hogh B: Differential plasma microRNA profiles in HBeAg positive and HBeAg negative children with chronic hepatitis B. PLoS One 2013, 8(3):e58236.
• [24]Shwetha S, Gouthamchandra K, Chandra M, Ravishankar B, Khaja MN, Das S: Circulating miRNA profile in HCV infected serum: novel insight into pathogenesis. Sci Rep 2013, 3:1555.
• [25]Lagatie O, Tritsmans L, Stuyver LJ: The miRNA world of polyomaviruses. Virol J 2013, 10:268. BioMed Central Full Text
• [26]Plavina T, Berman M, Njenga M, Crossman M, Lerner M, Gorelik L, Simon K, Schlain B, Subramanyam M: Multi-site analytical validation of an assay to detect anti-JCV antibodies in human serum and plasma. J Clin Virol 2012, 53(1):65-71.
• [27]Mestdagh P, Feys T, Bernard N, Guenther S, Chen C, Speleman F, Vandesompele J: High-throughput stem-loop RT-qPCR miRNA expression profiling using minute amounts of input RNA. Nucleic Acids Res 2008, 36(21):e143.
• [28]D’Haene B, Mestdagh P, Hellemans J, Vandesompele J: miRNA expression profiling: from reference genes to global mean normalization. Meth Mol Biol 2012, 822:261-272.
• [29]Benjamini Y, Hochberg Y: Controlling the false discovery rate: a practical and powerful approach to multiple testing. J Roy Stat Soc B 1995, 57(1):289-300.
• [30]Antonsson A, Green AC, Mallitt KA, O’Rourke PK, Pawlita M, Waterboer T, Neale RE: Prevalence and stability of antibodies to the BK and JC polyomaviruses: a long-term longitudinal study of Australians. J Gen Virol 2010, 91(Pt 7):1849-1853.
• [31]Egli A, Infanti L, Dumoulin A, Buser A, Samaridis J, Stebler C, Gosert R, Hirsch HH: Prevalence of polyomavirus BK and JC infection and replication in 400 healthy blood donors. J Infect Dis 2009, 199(6):837-846.
• [32]Jeong BH, Lee KH, Choi EK, Kim K, Kim YS: Genotyping of the JC virus in urine samples of healthy Korean individuals. J Med Virol 2004, 72(2):281-289.
• [33]Noble WS: How does multiple testing correction work? Nat Biotechnol 2009, 27(12):1135-1137.
• [34]Dalianis T, Hirsch HH: Human polyomaviruses in disease and cancer. Virology 2013, 437(2):63-72.
• [35]DeCaprio JA, Garcea RL: A cornucopia of human polyomaviruses. Nat Rev Microbiol 2013, 11(4):264-276.
• [36]Korup S, Rietscher J, Calvignac-Spencer S, Trusch F, Hofmann J, Moens U, Sauer I, Voigt S, Schmuck R, Ehlers B: Identification of a novel human polyomavirus in organs of the gastrointestinal tract. PLoS One 2013, 8(3):e58021.
• [37]Van Ghelue M, Khan MT, Ehlers B, Moens U: Genome analysis of the new human polyomaviruses. Rev Med Virol 2012, 22(6):354-377.
• [38]Zaragosi LE, Wdziekonski B, Brigand KL, Villageois P, Mari B, Waldmann R, Dani C, Barbry P: Small RNA sequencing reveals miR-642a-3p as a novel adipocyte-specific microRNA and miR-30 as a key regulator of human adipogenesis. Genome Biol 2011, 12(7):R64. BioMed Central Full Text
• [39]Kuchen S, Resch W, Yamane A, Kuo N, Li Z, Chakraborty T, Wei L, Laurence A, Yasuda T, Peng S, Hu-Li J, Lu K, Dubois W, Kitamura Y, Charles N, Sun HW, Muljo S, Schwartzberg PL, Paul WE, O’Shea J, Rajewsky K, Casellas R: Regulation of microRNA expression and abundance during lymphopoiesis. Immunity 2010, 32(6):828-839.
• [40]Farazi TA, Horlings HM, Ten Hoeve JJ, Mihailovic A, Halfwerk H, Morozov P, Brown M, Hafner M, Reyal F, van Kouwenhove M, Kreike B, Sie D, Hovestadt V, Wessels LF, van de Vijver MJ, Tuschl T: MicroRNA sequence and expression analysis in breast tumors by deep sequencing. Canc Res 2011, 71(13):4443-4453.
• [41]Kruhoffer M, Dyrskjot L, Voss T, Lindberg RL, Wyrich R, Thykjaer T, Orntoft TF: Isolation of microarray-grade total RNA, microRNA, and DNA from a single PAXgene blood RNA tube. J Mol Diagn 2007, 9(4):452-458.
• [42]Debey-Pascher S, Chen J, Voss T, Staratschek-Jox A: Blood-based miRNA preparation for noninvasive biomarker development. Meth Mol Biol 2012, 822:307-338.